Julie Maréchal-Jamil 

Director Biosimilars Policy & Science - Medicines for Europe


Leading the Biosimilar Medicines Group, a sector group of Medicines for Europe, Julie aims at creating and nurturing dialogue with experts and partners across healthcare systems. The main objective of the Biosimilar Medicines Group is to support and facilitate the design, evolution and implementation of policies aimed at fostering greater access to biologic therapies and other healthcare products and services, with biosimilar medicines use as catalyst for smart investment and innovation in health. 

Since 2015, she has been actively involved, including in leadership positions, in the IGBA Biosimilars Committee activities contributing to Global policy discussions. 

Her knowledge and understanding of the scientific, regulatory, pharmaceutical and health policy environments at EU and global levels, greatly supports her effective engagement with all the players involved in the EU and global ecosystems.  

Part of the Medicines for Europe Management Team, she is responsible for People & Organisation matters, focused on employees’ professional growth. 

With a MSc in Pharmacology, she previously worked in the pharmaceutical industry.